在英国高等医疗中心停止使用雅努斯激酶抑制剂:一项回顾性研究
Katie Bland1, Ameen Jubber2, Sujata Ganguly2
1Medicine, University Hospitals of Leicester NHS Trust, Leicester, GBR.
Cureus
|December 30, 2025
概括
在炎症性关节炎中,关节激酶 (JAK) 抑制剂的停用通常是由于无效或副作用. 药物的使用率因药物而异,有些药物的早期停用率较高,需要进一步的安全研究.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 简氏激酶 (JAK) 抑制剂越来越多地用于炎症性关节炎.
- 了解停药模式对于优化治疗策略至关重要.
研究的目的:
- 确定患有炎症性关节炎的患者中JAK抑制剂中止率和原因.
- 为了确定与停药相关的因素.
主要方法:
- 在2018年5月至2023年10月期间,对400名被处方JAK抑制剂 (托法西提尼布,巴里西提尼布,阿巴西提尼布,菲尔戈提尼布) 的患者进行了回顾性分析.
- 统计分析以将停止治疗的原因与患者的基线特征相关联.
主要成果:
- 在400名患者中,有102名患者 (25.5%) 停止服用JAK抑制剂.
- 停药的主要原因是无效 (34.3%) 和副作用 (24.5%).
- 托法西提尼布和巴里西提尼布的整体停药率较高;乌帕达西提尼布和菲尔戈提尼布的早期停药率较高.
结论:
- 不有效性和副作用是JAK抑制剂在炎症性关节炎中中止的主要驱动因素.
- 不同的JAK抑制剂之间停药时间存在显著差异.
- 需要进一步的研究来评估这些药物的长期安全性.
关键词:
巴里西提尼布 (baricitinib) 是一种药物.菲尔戈提尼布 (filgotinib) 是一种药物.雅克抑制剂 雅克抑制剂亚努斯酶 (jak) 的使用这是一种 janus 激酶抑制剂.类风湿性关节炎 类风湿性关节炎类风湿病学 类风湿病学托法西提尼布 (tofacitinib) 是一种在此之前,upadacitinib 已经在使用中.更多相关视频
06:45Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
15.7K
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
674
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
